Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History YMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics YMAB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Y mAbs Therapeutics

YMAB
Current price
4.22 USD -0.05 USD (-1.17%)
Last closed 4.30 USD
ISIN US9842411095
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 194 771 952 USD
Yield for 12 month -62.62 %
1Y
3Y
5Y
10Y
15Y
YMAB
21.11.2021 - 28.11.2021

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey. Address: 202 Carnegie Center, Princeton, NJ, United States, 08540

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.70 USD

P/E Ratio

Dividend Yield

Financials YMAB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures YMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+87 685 000 USD

Last Year

+84 819 000 USD

Current Quarter

+20 904 000 USD

Last Quarter

+26 495 000 USD

Current Year

+72 434 000 USD

Last Year

+73 403 000 USD

Current Quarter

+17 903 000 USD

Last Quarter

+18 653 000 USD
EBITDA -23 374 000 USD
Operating Margin TTM -26.88 %
Price to Earnings
Return On Assets TTM -12.62 %
PEG Ratio
Return On Equity TTM -29.93 %
Wall Street Target Price 14.70 USD
Revenue TTM 88 658 000 USD
Book Value 1.98 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 4.90 %
Dividend Yield
Gross Profit TTM 72 553 000 USD
Earnings per share -0.64 USD
Diluted Eps TTM -0.64 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -31.85 %

Stock Valuation YMAB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 119.05
Enterprise Value Revenue 1.51
Price Sales TTM 2.20
Enterprise Value EBITDA -0.43
Price Book MRQ 2.16

Technical Indicators YMAB

For 52 Weeks

3.55 USD 16.11 USD
50 Day MA 4.45 USD
Shares Short Prior Month 2 688 928
200 Day MA 7.83 USD
Short Ratio 12.94
Shares Short 2 652 742
Short Percent 6.94 %